MTOR and inflammatory bowel disease: In another example, the clinically approved drug metformin has been shown to activate AMPK and suppress mTOR signaling, thereby reducing Th17-driven inflammation while enhancing Treg differentiation in models of inflammatory bowel disease (IBD).